A randomized, double-blind, placebo-controlled, dose ranging Phase 2 study of brivekimig followed by a maintenance period in participants with moderate to severe hidradenitis suppurativa
About this study
To evaluate the efficacy and safety of SAR442970 in participants with hidradenitis suppurativa over a 16-week placebo-controlled treatment period followed by a 32-week extension period on varying doses of SAR442970.
Eligible participants may be invited to continue treatment for in a Long-term extension period (also open label).
- ClinicalTrials.gov Identifier: NCT07170917
- Sanofi Reference No: DRI19220
- HREC Reference Number: HREC/121703/Alfred-2025
Who is eligible to participate?
- ≥18 years of age with a diagnosis of HS based on clinical history and physical examination for at least 6 months prior to the Baseline visit.
- No other active skin disease or condition (eg, bacterial, fungal, or viral infection)
- No recent serious infections, including those needing hospitalisation or IV treatment within 30 days, or oral treatment within 14 days before the Baseline visit.
Please note, other eligibility criteria may apply.
What is involved?
- Attending the study clinic for regular visits over about 60 weeks (around 15–17 visits)
- Receiving injections under the skin every 2 weeks
- Completing questionnaires about your symptoms and quality of life
- Undergoing skin checks and physical examinations
- Having safety blood tests and other routine health assessments
Contact
Alfred Dermatology trials’ study coordinator: E: dermtrials@alfred.org.au | T: 03 9076 8592